Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 31, 2013, Pages 12703-12708

  Mahony, Chris ^a   Erskine, Lynda ^a   Niven, Jennifer ^b   Greig, Nigel H ^c   Figg, William Douglas ^d   Vargesson, Neil ^a  

^a Dept Anat Sch Med Sci U   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c NATIONAL INSTITUTE ON AGING   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cox2; CPS49; Cytoskeleton; Drug screening

Indexed keywords

LENALIDOMIDE; POMALIDOMIDE; THALIDOMIDE; ANGIOGENESIS INHIBITOR; NEUROTOXIN; TERATOGENIC AGENT;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL; CELL SPECIFICITY; CHICKEN; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EMBRYO; EMBRYO DEVELOPMENT; ERYTHEMA NODOSUM LEPROSUM; IN VITRO STUDY; MULTIPLE MYELOMA; NERVE FIBER GROWTH; NONHUMAN; PRIORITY JOURNAL; SEQUOIA; TERATOGENESIS; VESSEL; ZEBRA FISH; ANALOGS AND DERIVATIVES; ANIMAL; CHICK EMBRYO; DRUG EFFECTS; EMBRYOLOGY; METABOLISM; NEURITE; SPECIES DIFFERENCE;

ANGIOGENESIS INHIBITORS; ANIMALS; CHICK EMBRYO; CHICKENS; NEOVASCULARIZATION, PHYSIOLOGIC; NEURITES; NEUROTOXINS; SPECIES SPECIFICITY; TERATOGENS; THALIDOMIDE; ZEBRAFISH;

EID: 84881091385     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1307684110     Document Type: Article

References (42)

1. Smithells RW, Newman CG (1992) Recognition of thalidomide defects. J Med Genet 29(10):716-723.
2. Vargesson N (2009) Thalidomide-induced limb defects: Resolving a 50-year-old puzzle. Bioessays 31(12):1327-1336.
3. Franks ME, Macpherson GR, Figg WD (2004) Thalidomide. Lancet 363(9423): 1802-1811.
4. Delforge M, et al. (2010) Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 11(11):1086-1095.
5. Richardson PG, et al. (2012) Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 26(4):595-608.
6. Schuler-Faccini L, et al. (2007) New cases of thalidomide embryopathy in Brazil. Birth Defects Res A Clin Mol Teratol 79(9):671-672.
7. Vianna FS, et al. (2013) Recognition of the phenotype of thalidomide embryopathy in countries endemic for leprosy: New cases and review of the main dysmorphological findings. Clin Dysmorphol 22(2):59-63.
8. Andhavarapu S, Roy V (2013) Immunomodulatory drugs in multiple myeloma. Expert Rev Hematol 6(1):69-82.
9. Saini N, Mahindra A (2013) Novel immunomodulatory compounds in multiple myeloma. Expert Opin Investig Drugs 22(2):207-215.
10. Palumbo A, Freeman J, Weiss L, Fenaux P (2012) The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes. Expert Opin Drug Saf 11(1): 107-120.
11. Voorhees PM, Laubach J, Anderson KC, Richardson PG (2013) Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. Blood 121(5):858.
12. Christian MS, et al. (2007) Evaluation of the developmental toxicity of lenalidomide in rabbits. Birth Defects Res B Dev Reprod Toxicol 80(3):188-207.
13. Lacy MQ, et al. (2009) Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 27(30):5008-5014.
14. Richardson PG, et al. (2013) Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 121(11):1961-1967.
15. Schey SA, et al. (2004) Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 22(16):3269-3276.
16. Ferguson GD, et al. (2007) Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2. J Clin Immunol 27(2): 210-220.
17. Fujita J, Mestre JR, Zeldis JB, Subbaramaiah K, Dannenberg AJ (2001) Thalidomide and its analogues inhibit lipopolysaccharide-mediated Iinduction of cyclooxygenase-2. Clin Cancer Res 7(11):3349-3355.
18. Muller GW, et al. (1999) Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 9(11):1625-1630.
19. Ruchelman AL, et al. (2013) Isosteric analogs of lenalidomide and pomalidomide: synthesis and biological activity. Bioorg Med Chem Lett 23(1):360-365.
20. Renshaw SA, et al. (2006) A transgenic zebrafish model of neutrophilic inflammation. Blood 108(13):3976-3978.
21. Moreira AL, et al. (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177(6):1675-1680.
22. Ema M, et al. (2010) Fetal malformations and early embryonic gene expression response in cynomolgus monkeys maternally exposed to thalidomide. Reprod Toxicol 29(1):49-56.
23. Ito T, et al. (2010) Identification of a primary target of thalidomide teratogenicity. Science 327(5971):1345-1350.
24. Knobloch J, Shaughnessy JD, Jr., Rüther U (2007) Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway. FASEB J 21(7):1410-1421.
25. Lenz W, Knapp K (1962) Thalidomide embryopathy. Arch Environ Health 5:100-105.
26. Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N (2009) Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci USA 106(21):8573-8578.
27. Vargesson N (2011) Reproductive and Developmental Toxicology, ed Gupta R (Academic, London), pp 395-406.
28. Yabu T, et al. (2005) Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood 106(1):125-134.
29. Lawson ND, Weinstein BM (2002) In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol 248(2):307-318.
30. Erskine L, et al. (2011) VEGF signaling through neuropilin 1 guides commissural axon crossing at the optic chiasm. Neuron 70(5):951-965.
31. Greig NH, et al. (2004) Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases. Acta Neurobiol Exp (Warsz) 64(1):1-9.
32. Lopez-Girona A, et al. (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26(11):2326-2335.
33. Tamilarasan KP, et al. (2006) Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells. BMC Cell Biol 7:17.
34. Hoffmann M, et al. (2013) Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother Pharmacol 71(2): 489-501.
35. Lu L, et al. (2009) The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 77(2):78-86.
36. Meganathan K, et al. (2012) Identification of thalidomide-specific transcriptomics and proteomics signatures during differentiation of human embryonic stem cells. PLoS ONE 7(8):e44228.
37. Siamwala JH, et al. (2012) Nitric oxide rescues thalidomide mediated teratogenicity. Sci Rep 2:679.
38. Dredge K, et al. (2005) Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69(1-2):56-63.
39. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC (2009) Multiple myeloma. Lancet 374(9686):324-339.
40. Ribatti D, Mangialardi G, Vacca A (2012) Antiangiogenic therapeutic approaches in multiple myeloma. Curr Cancer Drug Targets 12(7):768-775.
41. Peltier AC, Russell JW (2006) Advances in understanding drug-induced neuropathies. Drug Saf 29(1):23-30.
42. Adams RH, Eichmann A (2010) Axon guidance molecules in vascular patterning. Cold Spring Harb Perspect Biol 2(5):a001875.